Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial

作者：Jia Zhong, Jun Zhao, Jianchun Duan, Jian Fang, Kailun Fei, Xiaoyan Li, Jiayan Chen, Zhijie Wang, Qian Chu, Yan Yu, Zhe Liu, Li Zhang, Yanqiu Zhao, Xingya Li, Lin Wu, Ligang Xing, Wu Zhuang, Xuefeng Fang, Jianhua Chang, Yueyin Pan, Xiaorong Dong, Lian Liu, Chunmei Bai, Pinhua Pan, Qibin Song, Bo Jin, Baoshan Cao, Feng Ye, Jianhua Shi, Kejing Tang, Andrea Wang‐Gillam, Yuli Ding, Chao Bi, Yang Shao, Jiaohui Pang, Rui Wan, Boyang Sun, Jiachen Xu, Jie Wang, Jie Wang, Jia Zhong, Jun Zhao, Jianchun Duan, Jian Fang, Kailun Fei, Xiaoyan Li, Jiayan Chen, Zhijie Wang, Qian Chu, Yan Yu, Zhe Liu, Li Zhang, Yanqiu Zhao, Xingya Li, Lin Wu, Ligang Xing, Wu Zhuang, Xuefeng Fang, Jianhua Chang, Yueyin Pan, Xiaorong Dong, Lian Liu, Chunmei Bai, Pinhua Pan, Qibin Song, Bo Jin, Baoshan Cao, Feng Ye, Jianhua Shi, Kejing Tang, Andrea Wang-Gillam, Yuli Ding, Chao Bi, Yang Shao, Jiaohui Pang, Rui Wan, Boyang Sun, Jiachen Xu, Jian Zhang, Jie Wang, Jian Zhang, Qun Hu, Huizhen Fan, Nong Yang, Qiao Li, Alan Xiao, Xin Sun, Ting Liu, Mengmeng Zhao, Ting Liu, Zhen Pang, Jun Yang, Hui Sun, Shizong Hu, Xiaonan Wang, Xian Zhang, Sha Wang, Na Bai, Shali Li, Y. Hu · 发表于：The Lancet Respiratory Medicine · 年份：2025 · DOI：10.1016/s2213-2600(25)00258-9 · 被引用次数：10 · 研究领域：Lung Cancer Treatments and Mutations、Protein Kinase Regulation and GTPase Signaling、PI3K/AKT/mTOR signaling in cancer